Agenus (NASDAQ:AGEN) Receives "Neutral" Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN - Free Report) in a report released on Wednesday,Benzinga reports.

Several other research analysts have also recently issued reports on the company. B. Riley reissued a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Robert W. Baird dropped their price objective on Agenus from $6.00 to $3.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 12th. Finally, StockNews.com raised Agenus from a "sell" rating to a "hold" rating in a research note on Friday, March 21st. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $8.75.

Agenus Trading Down 0.3 %

AGEN traded down $0.01 during trading on Wednesday, reaching $3.10. 246,986 shares of the company were exchanged, compared to its average volume of 577,783. Agenus has a 52 week low of $1.38 and a 52 week high of $19.69. The firm has a 50 day moving average of $2.10 and a 200 day moving average of $2.97. The stock has a market cap of $78.46 million, a P/E ratio of -0.27 and a beta of 1.58.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to the consensus estimate of $30.09 million. As a group, analysts forecast that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agenus

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC grew its position in Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 4,924 shares during the period. Apollon Wealth Management LLC grew its holdings in Agenus by 25.0% during the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 5,000 shares during the period. State Street Corp increased its holdings in Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company's stock valued at $2,563,000 after purchasing an additional 9,731 shares during the last quarter. Corton Capital Inc. acquired a new stake in shares of Agenus in the 4th quarter valued at approximately $36,000. Finally, Virtu Financial LLC bought a new stake in shares of Agenus in the 4th quarter valued at $51,000. 61.46% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.